View : 53 Download: 0

Omission of Breast Surgery in Predicted Pathologic Complete Response after Neoadjuvant Systemic Therapy: A Multicenter, Single-Arm, Non-inferiority Trial

Title
Omission of Breast Surgery in Predicted Pathologic Complete Response after Neoadjuvant Systemic Therapy: A Multicenter, Single-Arm, Non-inferiority Trial
Authors
Jung, Ji-JungCheun, Jong-HoKim, Soo-YeonKoh, JiwonRyu, Jai MinYoo, Tae-KyungShin, Hee-ChulAhn, Sung GwePark, SehoLim, WoosungNam, Sang-EunPark, Min HoKim, Ku SangKang, TaewooLee, JeeyeonYoun, Hyun JoKim, Yoo SeokYoon, Chang IkKim, Hong-KyuMoon, Hyeong-GonHan, WonshikCho, NariyaKim, Min KyoonLee, Han-Byoel
Ewha Authors
임우성
SCOPUS Author ID
임우성scopus
Issue Date
2024
Journal Title
JOURNAL OF BREAST CANCER
ISSN
1738-6756JCR Link

2092-9900JCR Link
Citation
JOURNAL OF BREAST CANCER vol. 27, no. 1, pp. 61 - 71
Keywords
BiopsyBreast NeoplasmsClinical TrialMulticenter StudyNeoadjuvant Therapy
Publisher
KOREAN BREAST CANCER SOC
Indexed
SCIE; SCOPUS; KCI WOS
Document Type
Article
Abstract
Purpose: Advances in chemotherapeutic and targeted agents have increased pathologic complete response (pCR) rates after neoadjuvant systemic therapy (NST). Vacuum-assisted biopsy (VAB) has been suggested to accurately evaluate pCR. This study aims to confirm the non-inferiority of the 5-year disease-free survival of patients who omitted breast surgery when predicted to have a pCR based on breast magnetic resonance imaging (MRI) and VAB after NST, compared with patients with a pCR who had undergone breast surgery in previous studies. Methods: The Omission of breast surgery for PredicTed pCR patients wIth MRI and vacuum- assisted bIopsy in breaST cancer after neoadjuvant systemic therapy (OPTIMIST) trial is a prospective, multicenter, single-arm, non-inferiority study enrolling in 17 tertiary care hospitals in the Republic of Korea. Eligible patients must have a clip marker placed in the tumor and meet the MRI criteria suggesting complete clinical response (post-NST MRI size <= 1 cm and lesion-to-background signal enhancement ratio <= 1.6) after NST. Patients will undergo VAB, and breast surgery will be omitted for those with no residual tumor. Axillary surgery can also be omitted if the patient was clinically node-negative before and after NST and met the stringent criteria of MRI size <= 0.5 cm. Survival and efficacy outcomes are evaluated over five years. Discussion: This study seeks to establish evidence for the safe omission of breast surgery in exceptional responders to NST while minimizing patient burden. The trial will address concerns about potential undertreatment due to false-negative results and recurrence as well as improved patient-reported quality of life issues from the omission of surgery. Successful completion of this trial may reshape clinical practice for certain breast cancer subtypes and lead to a safe and less invasive approach for selected patients.
DOI
10.4048/jbc.2023.0265
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE